Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Cash Flows From Operating Activities:
Net loss	$ (62,144)	$ (51,070)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	20,965	19,493
Stock-based compensation	9,654	9,754
Accretion of debt discount, recorded to interest expense on 2018 Convertible Notes (Note 14)	4,236	4,246
Amortization of deferred financing costs, recorded to interest expense on 2018 Convertible Notes (Note 14)	491	521
Bad debt recovery	0	(15)
Unrealized foreign currency exchange gain	(18)	(155)
Change in cash surrender value of corporate owned life insurance	(266)	0
Research and development expense recognized for the value of common stock issued in connection with QAPZOLA (Note 16(b)(x)) and ROLONTIS (Note 16(b)(xiii)) milestone achievements	0	2,419
Deferred tax liabilities	154	(40)
Income tax recognition on unrealized gain for available-for-sale securities	(2,068)	0
Change in fair value of contingent consideration related to the Talon and EVOMELA acquisitions (Note 9)	3,236	1,249
Changes in operating assets and liabilities:
Accounts receivable, net	2,143	(12,040)
Other receivables	(88)	5,571
Inventories	554	(6,768)
Prepaid expenses	972	804
Other assets	183	(2,095)
Accounts payable and other accrued obligations	(2,954)	(6,595)
Accrued payroll and benefits	(1,343)	(451)
FOLOTYN development liability (Note 15)	(704)	(526)
Acquisition related contingent obligations	0	(1,300)
Deferred revenue	(483)	(1,417)
Other long-term liabilities	1,523	1,321
Net cash used in operating activities	(25,957)	(37,094)
Cash Flows From Investing Activities:
Payment for corporate-owned life insurance premiums	(601)	0
Redemption of mutual funds	(1)	(1)
Purchases of property and equipment	(412)	(61)
Net cash used in investing activities	(1,014)	(62)
Cash Flows From Financing Activities:
Proceeds from exercise of stock options	3,051	190
Proceeds from sale of stock under employee stock purchase plan	406	383
Purchase and retirement of restricted stock to satisfy employees' tax liability at vesting	(1,476)	(829)
Payment of contingent consideration related to EVOMELA acquisition (Note 9(b))	0	(4,700)
Proceeds from common shares sold under an at-market-issuance sales agreement (Note 18)	113,966	73,869
Dividends paid upon conversion of Series E Convertible Voting Preferred Stock (Note 18)	0	(6)
Net cash provided by financing activities	115,947	68,907
Effect of exchange rates on cash and equivalents	270	113
Net increase in cash and cash equivalents	89,246	31,864
Cash and cash equivalents—beginning of period	158,222	139,741
Cash and cash equivalents—end of period	247,468	171,605
Supplemental disclosure of cash flow information:
Cash paid for income taxes	10	11
Cash paid for interest	$ 1,513	$ 1,650